{
    "patient": {
        "Name": "Michael Bennett",
        "DateOfBirth": "1966-07-03",
        "Sex": "Female",
        "Diagnosis": "Adenocarcinoma",
        "BodyPart": "Prostate",
        "Physician": "Dr. Michelle Wilson",
        "TreatingInstitution": "Jones, Obrien and Williams"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Prostate",
            "CollectedDate": "2023-12-23",
            "ReceivedDate": "2023-12-23",
            "TumorPercentage": "78%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2023-12-24",
            "ReceivedDate": "2023-12-24"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "CTNNB1",
                "DNA Alteration": "c.101G>T",
                "GeneMutation": "p.T41I Stopgain-LOF",
                "VariantAlleleFraction": "20.35%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "IDH1",
                "DNA Alteration": "c.395G>T",
                "GeneMutation": "p.S45P Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "7.96%"
            },
            {
                "Gene": "JAK2",
                "DNA Alteration": "c.1848_1849delinsCT",
                "GeneMutation": "p.S37C Spliceregionvariant-LOF",
                "VariantAlleleFraction": "12.16%"
            },
            {
                "Gene": "NOTCH1",
                "DNA Alteration": "c.3587G>A",
                "GeneMutation": "p.R132L Spliceregionvariant-LOF",
                "VariantAlleleFraction": "17.91%"
            },
            {
                "Gene": "MPL",
                "DNA Alteration": "c.1544G>T",
                "GeneMutation": "p.T875N Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "8.17%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": []
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "33 m/Mb",
            "Tmbpercentile": "8%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "High"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "ABL1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.A34V Stopgain-LOF",
                "VariantAlleleFraction": "22.82%"
            },
            {
                "Gene": "HRAS",
                "DNA Alteration": "c.35_36delinsTA",
                "GeneMutation": "p.G12D Frameshift-LOF",
                "VariantAlleleFraction": "8.7%"
            },
            {
                "Gene": "EZH2",
                "DNA Alteration": "c.1936T>G",
                "GeneMutation": "p.Y646F Frameshift-LOF",
                "VariantAlleleFraction": "8.8%"
            },
            {
                "Gene": "PDGFRB",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.T681I Frameshift-LOF",
                "VariantAlleleFraction": "1.01%"
            },
            {
                "Gene": "JAK3",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.L857P Frameshift-GOF",
                "VariantAlleleFraction": "9.76%"
            },
            {
                "Gene": "DNMT3A",
                "DNA Alteration": "c.2711C>T",
                "GeneMutation": "p.P904L Stopgain-LOF",
                "VariantAlleleFraction": "2.83%"
            },
            {
                "Gene": "MSH2",
                "DNA Alteration": "c.1906G>C",
                "GeneMutation": "p.A636P Spliceregionvariant-GOF",
                "VariantAlleleFraction": "8.24%"
            }
        ],
        "Germline": [
            {
                "Gene": "BTK",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.C481X Frameshift-GOF",
                "Condition": "agent"
            }
        ]
    },
    "low coverage regions": [
        "ARHGAP45",
        "PAX5"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "CTNNB1",
                "DNA Alteration": "c.101G>T",
                "GeneMutation": "p.T41I Stopgain-LOF",
                "description": "NFE2L2 acts as a transcription factor for proteins that contain an antioxidant response element (ARE) within their promoter sequence. Genes that contain ARE are involved in injury and inflammation response. Activating mutations and overexpression of NFE2L2 are associated with cancer progression.",
                "VariantAlleleFraction": "20.35%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "IDH1",
                "DNA Alteration": "c.395G>T",
                "GeneMutation": "p.S45P Missensevariant(exon2)-GOF",
                "description": "BCL11B encodes a C2H2-type zinc finger protein that functions as a transcriptional repressor and plays a role in T-cell development and survival. Loss of function mutations, copy number loss, and fusions resulting in the underexpression of BCL11B are associated with cancer progression.",
                "VariantAlleleFraction": "7.96%"
            },
            {
                "Gene": "JAK2",
                "DNA Alteration": "c.1848_1849delinsCT",
                "GeneMutation": "p.S37C Spliceregionvariant-LOF",
                "description": "RBM10 encodes a protein that contains a RNA-binding motif and interacts with RNA homopolymers, and is thought to function in regulating alternative splicing. Loss of function mutations and copy number loss of RBM10 are associated with cancer progression.",
                "VariantAlleleFraction": "12.16%"
            },
            {
                "Gene": "NOTCH1",
                "DNA Alteration": "c.3587G>A",
                "GeneMutation": "p.R132L Spliceregionvariant-LOF",
                "description": "STK11 (LKB1) encodes an enzyme in the serine/threonine kinase family that is responsible for maintaining energy metabolism and cellular polarization through the activation of AMP-activated protein kinase and other members of the AMPK family. The enzyme also acts as a tumor suppressor by regulating cell growth. Loss of function mutations, copy number loss, epigenetic variation, and underexpression of STK11 are associated with cancer progression.",
                "VariantAlleleFraction": "17.91%"
            },
            {
                "Gene": "MPL",
                "DNA Alteration": "c.1544G>T",
                "GeneMutation": "p.T875N Missensevariant(exon2)-GOF",
                "description": "TP53 encodes a protein that is a transcription factor that regulates the expression of genes involved in cell cycle arrest, apoptosis, and DNA repair. TP53 is a tumor suppressor gene that is mutated in many cancers. Mutations in TP53 are associated with cancer progression.",
                "VariantAlleleFraction": "8.17%"
            }
        ]
    },
    "clinical history": {
        "Date": "2023-12-18"
    },
    "other": {
        "ReportId": "5903",
        "ReportDate": "2023-12-25",
        "SignedBy": "Michelle Wilson",
        "Supervisor": "Dr. Christopher Perez"
    }
}